Dr. Annekathrin Haberland, Ph.D.
Dr. Haberland acts as Berlin Cures’ director of regulatory affairs and is also responsible for managing innovation and technology. She introduced aptamer technology to autoantibodies against G-protein coupled receptors after working for an extended period in the laboratory of Priv.-Doz.
Dr. Michael Böttger of the Max Delbrück Center for Molecular Medicine in Berlin-Buch, where she also developed non-viral DNA-vectors and studied protein-DNA-interaction. Dr. Haberland studied pharmacy at the Humboldt University of Berlin and received her Ph.D. in pathomechanisms of the heart and circulatory system with a focus on oxidative stress. She subsequently held several postdoctoral and research scientist positions.